Navigation Links
Expression of certain transporter proteins may predict resistance to drug therapy

Rome, Italy, Friday 18 June: The expression of a transporter protein called the Breast Cancer Resistance Protein (BCRP) in rheumatoid arthritis (RA) patients may indicate higher disease activity and could be a barrier to the effectiveness of disease-modifying antirheumatic drugs (DMARDs), according to the results of a study presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy.

In a Turkish study, researchers analysed specimens of synovium (the soft tissue that lines the surfaces within joints) from patients with RA who had undergone knee or hip replacement surgery. The presence of BCRP was reported in 41% of samples from RA patients, compared with 0% of samples in the healthy control group. The level of BCRP staining (a technique where a stain specific to a particular protein is used) was more prominent, indicating that the protein was being expressed at higher levels in cells actively involved in the immune response (macrophages, endothelial cells and fibroblasts).

Furthermore, of the 40% of RA patients with cells that showed a presence of BCRP, some had a higher concurrent disease activity score (DAS28, an index that rates scores of 28 tender and swollen joints) despite receiving treatment for their condition, when compared with patients without BCRP. Researchers noted that this difference was not statistically significant (4.320.32 vs 3.371.16, p>0.05).

"The results of our study show that the presence of BRCP was only detected in patients with RA and that arguably it is found more prominently in patients with high disease activity," said Dr. Umut Kalyoncu, Hacettepe University Rheumatology Department, Ankara, Turkey, and lead author of the study. "The BCRP protein is a pump involved in transporting substances across the cellular membrane. What we hypothesise is that, due to the location of the cells showing highest levels of BCRP, the presence of this protein may create a barrier for treatments entering the synovium of RA patients. Testing RA patients for the presence of BCRP may help us determine which patients will respond better to certain treatments."

Researchers screened samples using histochemical methods from seventeen patients (female n=14) with RA for the presence of p-glycoprotein (a protein involved in the transport of various molecules across cellular membranes), BCRP and multidrug resistance protein 1 and compared with samples taken from a control group of healthy controls and other inflammatory (ankylosing spondylitis, juvenile chronic arthritis) and non-inflammatory (osteoarthritis) rheumatic diseases. Prior to surgery, 53% of patients were taking methotrexate, 47% were taking sulphasalazine, 70% hydroxychloroquine, 18% leflunomide and 12% were taking anti-TNF drugs.


Contact: Rory Berrie
European League Against Rheumatism

Related medicine news :

1. “You Are Very Pretty”, Says Myeexpert As It Releases A Book, Poetic Expressions, Dedicated To The Beauty of Women.
2. Spanish gene expression data promise targeting of anti-angiogenesis treatment
3. Gene expression test reduces need for invasive heart muscle biopsy
4. Personal Tragedy Reveals Untapped Artistic Expression / Family Business Memorializes Loved Ones with Compassion During Grieving
5. Mechanical forces could affect gene expression
6. Hong Kong Government Invites Expressions of Interest in Development of Private Hospitals
7. New Tests for Prostate Cancer Might Bring More Certainty
8. Certain Popular Antidepressants Linked to Cataracts in Seniors
9. Genes Link to Certain Cancers Questioned
10. Challenging the use of routine repeated chest X-rays in certain patients
11. Drug now used to treat erectile dysfuncton may enhance delivery of herceptin to certain brain tumors
Post Your Comments:
(Date:11/25/2015)... ... ... “While riding the bus, I saw a passenger in a wheelchair drenched ... be a convenient and comfortable way to protect them from bad weather, so I ... travel during cold or inclement weather. In doing so, it ensures that the user ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract Development ... expansion of its current state of the art research, development and manufacturing facility ... increase its manufacturing capacity as well as to support its clients’ growing research ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to be thankful ... Create Real Impact awards. California Casualty is proud to support the contest ... distracted and reckless driving, the number one killer of young drivers. , Almost ...
(Date:11/24/2015)... Mississauga, ON (PRWEB) , ... November 24, 2015 , ... ... Deborah Williams without a referral for dental implants at her Mississauga, ON ... qualified and experienced in the placement of dental implants. , Missing teeth can ...
(Date:11/24/2015)... ... November 25, 2015 , ... Catalent ... for drugs, biologics, consumer health and global clinical supply services, today announced that ... Clinical Trial Supply East Asia Conference, to be held at the InterContinental Seoul ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... and BERN, Switzerland , November ... ARTORG Center for Biomedical Engineering Research of the University ... Division of Endocrinology, Diabetes and Clinical Nutrition of the ... start of an exclusive collaboration to develop a novel ... for the personalised delivery of insulin for diabetic patients ...
(Date:11/24/2015)... FLINT, Mich. , Nov. 24, 2015 Diplomat ... , Senior Vice President of Clinical Services, Education and Human ... (AIS) online webinar, "Oral Oncology Drugs: Health Plan Strategies for ... co-presenting with Beckie Fenrick , a consultant with the ... The webinar will ...
(Date:11/24/2015)... 24, 2015 iRhythm Technologies, Inc. , a leading ... announced that it will participate in the 27th Annual Piper Jaffray ... New York, NY . Kevin King , Chief ... 1, 2015 at 8:50am ET. --> ... . --> . --> iRhythm is ...
Breaking Medicine Technology: